Search
Displaying 571–580 of 624 for “retinal diseases”
-
Enhanced Implantable Miniature Telescope Moving into Clinical Trial for AMD Patients
Research NewsThe device is designed for people with late-stage AMD who have no treatment options
-
Aldeyra Launches Phase 2 Clinical Trial of Methotrexate Intravitreal Injections for RP
Research NewsLab studies showed the drug can effectively address the misfolded rhodopsin protein
-
Genentech-Roche Receives FDA Approval for Vabysmo for Treatment of Wet AMD and DME
Research NewsThis new treatment can reduce the frequency of injections into the eye
-
Kriya Therapeutics Licenses Emerging Foundation-Funded Dry AMD Gene Therapy
Research NewsThe Foundation Fighting Blindness is funding Bärb Rohrer, PhD, Medical University of South Carolina, to evaluate safety and efficacy of the gene therapy in a large animal model
-
Research News
Survey results will inform therapy developers and the agenda for a Patient-Focused Drug Development meeting with Food and Drug Administration representatives.
-
FDA Approves Genentech’s Susvimo for Treating Wet AMD
Research NewsThe approach significantly reduces the need for regular ocular injections.
-
Telling His Story of Resilience
Beacon StoriesChad has been working in the corporate world for the last 20 years. But after becoming the first blind executive to graduate from the Harvard Business School leadership program, he realized his purpose in life is to help others by sharing the lessons he learned while losing his eyesight. He can now add published author to his repertoire with his new book, Blind Ambition.
-
Apellis to Seek FDA Approval of its Dry AMD Drug
Research NewsKnown as APL-2, the drug met its primary endpoint in the OAKS clinical trial but not the DERBY trial
-
Seeing Through Your Disability
Beacon Stories30-year-old Lance Johnson is a video editor and podcaster living in Brooklyn, New York. Despite being diagnosed with retinitis pigmentosa (RP) at a young age, Lance has never let his RP change his drive and passion for creating.
-
Biogen’s Phase 3 Clinical Trial for its Choroideremia Gene Therapy Doesn’t Meet Endpoints
Research NewsAdditional results from the trial will be reported at a future scientific meeting
.png)
